Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis (July, 10.1007/s00535-022-01895-3, 2022)-MedSci.cn

Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis (July, 10.1007/s00535-022-01895-3, 2022)

Zhou, QF; Wang, XH; Li, RX; Wang, CM; Wang, JC; Xie, XY; Li, YL; Li, SQ; Mao, XH; Liang, P

Zhou, QF; Liang, P (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Intervent Ultrasound, 28 Fuxing Rd, Beijing 100853, Peoples R China.;Mao, XH (通讯作者)，Hunan Normal Univ, Hunan Prov Peoples Hosp, Dept Hepatobiliary Surg, Affiliated Hosp 1, Changsha 410002, Hunan, Peoples R China.

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis (July, 10.1007/s00535-022-01895-3, 2022)

科室

工具

服务